Radiosensitizing effect of BRAF inhibitors in BRAF-mutated melanoma

被引：0
|
作者：
Hecht, M. [1 ]
Grabenbauer, M. [1 ]
Fietkau, R. [1 ]
Distel, L. V. [1 ]
Heinzerling, L. [2 ]
机构：
[1] Univ Hosp Erlangen, Radiat Oncol, Erlangen, Germany
[2] Univ Hosp Erlangen, Dermatol, Erlangen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0408
引用
收藏
页码：35 / 35
页数：1
相关论文
共 50 条
  • [21] Intermittent Versus Continuous Dosing of MAPK Inhibitors in Treatment of BRAF-Mutated Melanoma
    de Moura, Coralie Reger
    Vercellino, Laetitia
    Jouenne, Fanelie
    Baroudjian, Barouyr
    Sadoux, Aurelie
    Louveau, Baptiste
    Delyon, Julie
    Serror, Kevin
    Goldwirt, Lauriane
    Merlet, Pascal
    Bouquet, Fanny
    Battistella, Maxime
    Lebb, Celeste
    Mourah, Samia
    TRANSLATIONAL ONCOLOGY, 2020, 13 (02): : 275 - 286
  • [22] Update on treatment strategy for patients with BRAF-mutated melanoma
    Namikawa, Kenjiro
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
    Flaherty, Keith T.
    Robert, Caroline
    Hersey, Peter
    Nathan, Paul
    Garbe, Claus
    Milhem, Mohammed
    Demidov, Lev V.
    Hassel, Jessica C.
    Rutkowski, Piotr
    Mohr, Peter
    Dummer, Reinhard
    Trefzer, Uwe
    Larkin, James M. G.
    Utikal, Jochen
    Dreno, Brigitte
    Nyakas, Marta
    Middleton, Mark R.
    Becker, Juergen C.
    Casey, Michelle
    Sherman, Laurie J.
    Wu, Frank S.
    Ouellet, Daniele
    Martin, Anne-Marie
    Patel, Kiran
    Schadendorf, Dirk
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (02): : 107 - 114
  • [24] The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
    Kim, Alex
    Cohen, Mark S.
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (09) : 907 - 916
  • [25] Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients
    Nijenhuis, C. M.
    Huitema, A. D. R.
    Blank, C.
    Haanen, J. B. A. G.
    van Thienen, J. V.
    Rosing, H.
    Schellens, J. H. M.
    Beijnen, J. H.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (01): : 125 - 128
  • [26] Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients
    Pier Francesco Ferrucci
    Marko Lens
    Emilia Cocorocchio
    Current Oncology Reports, 2021, 23
  • [27] Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients
    Ferrucci, Pier Francesco
    Lens, Marko
    Cocorocchio, Emilia
    CURRENT ONCOLOGY REPORTS, 2021, 23 (12)
  • [28] MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors
    Pinto, Rosamaria
    Strippoli, Sabino
    De Summa, Simona
    Albano, Anna
    Azzariti, Amalia
    Guida, Gabriella
    Popescu, Ondina
    Lorusso, Vito
    Guida, Michele
    Tommasi, Stefania
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (08) : 1027 - 1035
  • [29] FDA Approves Adjuvant Dabrafenib/Trametinib in BRAF-Mutated Melanoma
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (06) : 397 - 397
  • [30] Severe vitamin D deficiency associated with BRAF-mutated melanoma
    Fearfield, L.
    Nobbs, J.
    Petruckevitch, A.
    Harland, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (06) : 1343 - 1343
12345